Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma candidates to autologous transplant.
Mangiacavalli S et al. Leuk Lymphoma. 2014 Oct 27:1-8. [Epub ahead of print].

Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ et al. Ann Hematol. 2014 Oct 28. [Epub ahead of print].

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.
Offidani M et al. Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014.

A Phase 1 Trial of Single Agent Reolysin in Patients with Relapsed Multiple Myeloma.
Sborov DW et al. Clin Cancer Res. 2014 Oct 7. pii: clincanres.1404.2014. [Epub ahead of print].

The development of potential antibody-based therapies for myeloma.
Sherbenou DW et al. Blood Rev. 2014 Sep 28. pii: S0268-960X(14)00080-0. doi: 10.1016/j.blre.2014.09.011. [Epub ahead of print].

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma.
Orlowski RZ et al. Am J Hematol. 2014 Oct 8. doi: 10.1002/ajh.23868. [Epub ahead of print].

Efficacy of vinorelbine plus G-CSF for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Samaras P et al. Biol Blood Marrow Transplant. 2014 Sep 29. pii: S1083-8791(14)00601-6. doi: 10.1016/j.bbmt.2014.09.020. [Epub ahead of print].